Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.33 |
| ▸ | DYRK2 | Q92630 | 4/20 | 0.32 |
| ▸ | DRD2 | P14416 | 3/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 2/20 | 0.31 |
| ▸ | CASR | P41180 | 1/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14616813 | 0.98 | RIPK2 (0.41) | RIPK2KCNH2RPS6KA5DYRK2DRD2 | |
| SCHEMBL14616824 | 0.98 | RIPK2 (0.40) | RIPK2KCNH2RPS6KA5DYRK2DRD2 | |
| SCHEMBL14616825 | 0.95 | RIPK2 (0.40) | RIPK2KCNH2DYRK2DRD2MAP3K11 | |
| SCHEMBL14616807 | 0.93 | RIPK2 (0.40) | RIPK2 | |
| SCHEMBL14616826 | 0.90 | RIPK2 (0.38) | RIPK2DRD2KDM1ADRD3 | |
| SCHEMBL14616811 | 0.88 | TTK (0.38) | RIPK2CNR2 | |
| SCHEMBL2554752 | 0.86 | MAP3K11 (0.34) | KCNH2RPS6KA5DYRK2DRD2KDM1A | |
| SCHEMBL14616808 | 0.86 | RIPK2 (0.37) | RIPK2 | |
| SCHEMBL14616809 | 0.86 | RIPK2 (0.37) | RIPK2 | |
| SCHEMBL14616820 | 0.85 | RIPK2 (0.39) | RIPK2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K3 | RIPK2 255/4885KCNH2 1135/4885RPS6KA5 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.